Astellas Pharma Inc. · TSE:4503
Astellas Pharma — Q1 2017 Earnings Presentation
5 slides from Astellas Pharma's earnings presentation, July 2017
Slide 1: R&D Pipeline (As of July 2017) - Oncology (1/2)
R&D Pipeline (As of July 2017) Underlined items indicate changes from the previous announcement on April 27, 2017. Oncology (1/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks
Slide 2: Oncology (2/2)
Oncology (2/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form ASP4132 Cancer P-I Oral In-house AGS67E Lymphoid malignancies P-I Injection In-house (ADC technol
Slide 3: Urology and Nephrology
Urology and Nephrology *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form YM905 Muscarine M3 receptor antagonist Neurogenic detrusor overactivity in pediatric pati
Slide 4: Immunology and Neuroscience
Immunology and Neuroscience *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form FK949E Serotonin / dopamine antagonist Improvement of depressive symptoms associated
Slide 5: Others
Others *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form AMG 785 Anti-Sclerostin Osteoporosis for those at high risk of fracture Filed (Dec. 2016) / Japan Injecti
Astellas Pharma — Q1 2017 Earnings Presentation on 6ix